Dario Gutierrez, Ph.D.
Dario Gutierrez joined TRV as an Entrepreneur-in-Residence in 2021 where he focuses on helping build the next generation of high impact companies. Prior to TRV, Dario was the Vice President of Discovery and Innovation at TCR2 Therapeutics where he led the development of the company’s early pipeline, including the allogeneic platform, expansion to new targets, enhancements to overcome the tumor microenvironment, and application of the platform to autoimmunity. Previously, he was the Director and Head of Investigational Biology at the Merck Exploratory Science Center where he led multiple drug discovery efforts in Inflammatory Diseases, Immuno-Oncology and Vaccines. Prior to Merck, Dario was the Head of Immune Tolerance at Evelo Biosciences. Dario earned his Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University and completed Postdoctoral training at the German Cancer Research Center in Heidelberg, Germany.
Outside work, Dario enjoys spending time outdoors with his daughter, trail and long distance running, and skiing as much as possible during the winter.